Metastatic melanoma: LAG-3 antiboy reached the primary endpoint of PFS?

Metastatic melanoma: LAG-3 antiboy reached the primary endpoint of PFS? BMS announced that the phase 3 clinical trial of nivolumab combined with LAG-3 antibody Relatlimab for the treatment of metastatic melanoma reached the primary endpoint of PFS, and the study is still in progress to observe the secondary endpoint. The news itself is quite shocking and has been a potential target for several years…

I swiped my phone before going to bed and saw that BMS announced that nivolumab combined with LAG-3 antibody Relatlimab for the treatment of metastatic melanoma reached the primary end point of PFS in the phase 3 clinical trial, and the study is still ongoing to observe the secondary end point of OS

LAG-3 finally succeeded in the Phase III study for the first time, and BMS is also very hopeful to become the first company to succeed in the three immune checkpoints of PD-1, CTLA-4, and LAG-3.

But a few thoughts:

1. If the sample size is greater than 700, PFS wins. Usually the sample size guarantees that from a statistical point of view, a positive result is obtained when the absolute improvement value of PFS is not so high, so we still look forward to the research data

2. OS is not yet mature. Although OS is a secondary research endpoint, refer to the precedents of several previous research results of atezolizumab for first-line non-small cell lung cancer by the US FDA (approval depends on the benefits of OS), and there is no shortage of first-line melanoma Drugs (nivo single drug, nivo+ipi, pembro are all approved), it is expected that the significant benefits of OS are also very important, and the more this kind of disease does not lack effective treatment, the follow-up treatment has more subtle effects on OS, expect OS The result gives the answer

3. Melanoma has always been friendly to immunotherapy, and the only approved indication for CTLA-4 monotherapy

4. In the control group, nivo single drug has relatively general efficacy in the first line of melanoma, slightly worse than nivo combined with ipi and slightly worse than pembro single drug

PFS: nivo+ipi vs nivo 11.5 vs 6.9

5. IO has already been approved for the adjuvant treatment of melanoma, and it will be shunted for patients with advanced treatment

Relatlimab is currently undergoing research on gastric cancer and liver cancer, and we look forward to more excellent data to surprise us

Breakthroughs in new targets are often precious. Is LAG-3 a new hot model? More evidence is needed. 

(source:internet, reference only)

Disclaimer of medicaltrend.org